Published in Infect Immun on August 01, 2000
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Differences in components at delayed-type hypersensitivity reaction sites in mice immunized with either a protective or a nonprotective immunogen of Cryptococcus neoformans. Infect Immun (2002) 0.84
CTLA-4 blockade inhibits induction of Helicobacter pylori-associated gastritis in mice. Clin Exp Immunol (2004) 0.82
Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology (2002) 0.81
Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans. Infect Immun (2001) 0.78
Modulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory Molecules. Front Immunol (2016) 0.76
Immunoregulation in Fungal Diseases. Microorganisms (2016) 0.75
Belatacept and mediastinal histoplasmosis in a kidney transplant patient. J Nephropathol (2016) 0.75
The Yin and Yang of T cell costimulation. Science (1995) 15.19
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol (1995) 3.06
CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol (1991) 2.92
Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol (1996) 2.69
CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol (1998) 2.01
Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice. Infect Immun (1980) 1.88
Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med (1997) 1.72
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1993) 1.57
CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol (1998) 1.45
Regulation of CTLA-4 expression during T cell activation. J Immunol (1996) 1.44
Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun (1987) 1.39
Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol (1998) 1.38
Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun (1999) 1.35
Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. Int Immunol (1999) 1.31
CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection. Infect Immun (1999) 1.23
Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect Immun (1998) 1.23
Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response. Infect Immun (1993) 1.19
Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation? J Exp Med (1995) 1.13
CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans. J Immunol (1994) 1.10
Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1990) 1.05
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1994) 1.03
Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect Immun (1989) 0.99
MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol (1997) 0.98
Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J Immunol (1997) 0.94
Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun (1997) 0.91
Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun (1995) 0.89
CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection. Eur J Immunol (1998) 0.82
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun (1979) 2.76
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun (1977) 2.35
In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol (1982) 2.19
What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis (1998) 2.18
Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun (1991) 1.90
Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice. Infect Immun (1980) 1.88
Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun (1980) 1.77
WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost (2010) 1.69
Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol (1999) 1.69
Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun (1986) 1.61
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1993) 1.57
Skin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformans. Infect Immun (1974) 1.56
Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J Immunol (1983) 1.52
Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2). J Immunol (1985) 1.48
Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun (1991) 1.48
Natural cellular resistance of beige mice against Cryptococcus neoformans. J Immunol (1986) 1.44
Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells. Infect Immun (1986) 1.41
Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun (1997) 1.41
Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun (1995) 1.41
Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun (1987) 1.39
Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun (1999) 1.35
Uncompensated care by hospitals or public insurance for the poor. Does it make a difference? N Engl J Med (1986) 1.35
Effects of first-order Cryptococcus-specific T-suppressor cells on induction of cells responsible for delayed-type hypersensitivity. Infect Immun (1985) 1.34
Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis. Infect Immun (1988) 1.33
Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis. Infect Immun (1979) 1.32
Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun (1995) 1.31
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
A child with partial deletion of a G-group autosome. Am J Dis Child (1967) 1.27
Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest (1996) 1.24
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun (1989) 1.17
Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol (2000) 1.16
Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect Immun (1993) 1.11
In vitro effects of natural killer cells against Paracoccidioides brasiliensis yeast phase. Infect Immun (1984) 1.07
Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans. Infect Immun (1991) 1.06
Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1990) 1.05
Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol (1998) 1.04
T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection. J Infect Dis (1989) 1.04
Immunoadsorption of Cryptococcus-specific suppressor T-cell factors. Infect Immun (1986) 1.03
Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun (1994) 1.03
Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans. J Leukoc Biol (1990) 1.01
Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology (1997) 1.01
Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect Immun (1989) 0.99
The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice. Infect Immun (2000) 0.99
Induction of antigen-specific T suppressor cells by soluble Paracoccidioides brasiliensis antigen. Infect Immun (1988) 0.98
MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol (1997) 0.98
In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun (1982) 0.95
Characterization of an in vitro-stimulated, Cryptococcus neoformans-specific second-order suppressor T cell and its precursor. Infect Immun (1988) 0.95
Direct antimicrobial activity of T cells. Immunol Today (1995) 0.92
Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice. Infect Immun (1995) 0.91
Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun (1997) 0.91
K562 cell strains differ in their response to poliovirus infection. Virology (1995) 0.91
Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia (1999) 0.90
Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun (1995) 0.89
Characterization of efferent T suppressor cells induced by Paracoccidioides brasiliensis-specific afferent T suppressor cells. Infect Immun (1988) 0.87
Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.85
Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response. Infect Immun (1991) 0.85
Role of the C-C chemokine, TCA3, in the protective anticryptococcal cell-mediated immune response. J Immunol (1999) 0.84
Mechanisms for induction of L-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect Immun (1999) 0.84
Immunomodulation in the mycoses. J Med Vet Mycol (1992) 0.82
Intracardiac repair for anomalous pulmonary venous connection of right lung to inferior vena cava. Ann Thorac Surg (1971) 0.81
Mechanisms of cell-mediated immunity in fungal infection. J Med Vet Mycol (1994) 0.80
Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis. Scand J Immunol (2004) 0.77
Use of the prolene hernia system for inguinal hernia repair: retrospective, comparative time analysis versus other inguinal hernia repair systems. Am Surg (2001) 0.76
Cellular immunity in a cutaneous model of cryptococcosis. Infect Immun (1983) 0.75
A method for hyperthermic treatment of mouse skin. Lab Anim (1992) 0.75
Reason and rationality in health and human services delivery: an introduction. J Health Soc Policy (1998) 0.75
Ebstein's anomaly in an infant with D-1 trisomy syndrome. J Ky Med Assoc (1967) 0.75
Local anesthesia for gastric surgery in aged patients. J Am Geriatr Soc (1968) 0.75
Technology and the manufacture of madness: a new dimension. Int J Soc Psychiatry (1986) 0.75
Impact of unusual gastrointestinal problems on the treatment of tricyclic antidepressant overdose. Ann Emerg Med (1988) 0.75
Chromosomes in cleft-palate tissues. Lancet (1966) 0.75
Reason, the life-world, and health care delivery. J Health Soc Policy (1998) 0.75
Natural cell-mediated resistance against Cryptococcus neoformans: a possible role for natural killer (NK) cells. Curr Top Med Mycol (1985) 0.75
Postmodernism and clinical practice: a critical analysis of the disease model. Psychol Rep (1993) 0.75
Formation of the lanosterol system through biogenetic-type cyclization. J Am Chem Soc (1970) 0.75
Abdominal and pelvic imaging as part of liver-spleen scintigraphy for the detection of mesenteric bleeding in trauma. A case report. Clin Nucl Med (1984) 0.75
Heart 70--brain 25. Hemodynamic factors determining the medical management of angina. J Kans Med Soc (1979) 0.75
Factors associated with premature termination of psychotherapy by children. Adolescence (1995) 0.75
An exploration of factors associated with clients prematurely exiting psychiatric treatment: implications for the Community Mental Health Centers Act. J Health Soc Policy (1995) 0.75
Computerized clinical practice: promises and shortcomings. Psychol Rep (1986) 0.75
Why student nurses select OR nursing as a career. AORN J (1972) 0.75
Some thoughts about MIS implementation in drug abuse programs. Int J Addict (1982) 0.75
Soluble factors in tolerance and contact sensitivity to 2,4-dinitrofluorobenzene in mice. IV. Characterization of migration inhibition factor-producing lymphocytes and genetic requirements for activation. Eur J Immunol (1982) 0.75
The use of management by objectives in medical education enrichment programs. J Med Educ (1982) 0.75
Research note: Identifying "at risk" persons in community based research. Sociol Health Illn (1987) 0.75
Liposomes, a potential immunoadjuvant and carrier for a cryptococcal vaccine. J Pharm Sci (1998) 0.75
Directional coronary atherectomy in acute myocardial infarction. J Invasive Cardiol (1993) 0.75